Cobimetinib Sensitizes Cervical Cancer to Paclitaxel Via Suppressing Paclitaxel-Induced ERK Activation.Yuan Liu,Runsheng Zhao,Xiaomin Qin,Xiaogang Mao,Quan Li,Shanshan FangPharmacology(2022)引用 4|浏览4暂无评分关键词Cobimetinib,MAPK/ERK,Paclitaxel,Cervical cancerAI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要